antipyrine has been researched along with Cyst in 3 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A family with polycystic liver disease was investigated in order to evaluate the role of the liver in determining the serum high-density lipoprotein (HDL) level and its relationship to the rate of antipyrine elimination from plasma." | 7.66 | Low high-density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease. ( Ehnholm, C; Luoma, PV; Sotaniemi, EA, 1980) |
| "A family with polycystic liver disease was investigated in order to evaluate the role of the liver in determining the serum high-density lipoprotein (HDL) level and its relationship to the rate of antipyrine elimination from plasma." | 3.66 | Low high-density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease. ( Ehnholm, C; Luoma, PV; Sotaniemi, EA, 1980) |
| " Drug-metabolizing capacity in cases of polycystic non-parasitic liver disease was investigated using plasma antipyrine clearance as an index." | 3.66 | Impairment of drug metabolism in polycystic non-parasitic liver disease. ( Järvensivu, PM; Luoma, PV; Sotaniemi, EA; Sotaniemi, KA, 1979) |
| "Volumes of total liver, hepatic cysts, hepatic parenchyma, and total kidney were measured by a validated computed tomography (CT) technique." | 1.30 | Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. ( Bronner, T; Everson, GT; McKinley, C; Russ, P; Scherzinger, A; Sherstha, R; Showalter, R, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luoma, PV | 2 |
| Sotaniemi, EA | 2 |
| Ehnholm, C | 1 |
| Sherstha, R | 1 |
| McKinley, C | 1 |
| Russ, P | 1 |
| Scherzinger, A | 1 |
| Bronner, T | 1 |
| Showalter, R | 1 |
| Everson, GT | 1 |
| Järvensivu, PM | 1 |
| Sotaniemi, KA | 1 |
3 other studies available for antipyrine and Cyst
| Article | Year |
|---|---|
Low high-density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease.
Topics: Adult; Antipyrine; Apoproteins; Cysts; Female; Humans; Lipids; Lipoproteins, HDL; Liver; Liver Disea | 1980 |
Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease.
Topics: Antipyrine; Caffeine; Cysts; Estrogen Replacement Therapy; Female; Hormones; Humans; Kidney; Liver; | 1997 |
Impairment of drug metabolism in polycystic non-parasitic liver disease.
Topics: Adult; Antipyrine; Cysts; Female; Half-Life; Humans; Liver Diseases; Male; Metabolic Clearance Rate; | 1979 |